Leap Therapeutics, Inc. (NASDAQ:LPTX) Position Cut by Simplify Asset Management Inc.

Simplify Asset Management Inc. lowered its position in shares of Leap Therapeutics, Inc. (NASDAQ:LPTX) by 10.5% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 946,046 shares of the company’s stock after selling 110,849 shares during the period. Simplify Asset Management Inc. owned 2.47% of Leap Therapeutics worth $2,720,000 as of its most recent filing with the SEC.

A number of other large investors have also modified their holdings of the company. Geode Capital Management LLC grew its position in Leap Therapeutics by 18.0% in the 3rd quarter. Geode Capital Management LLC now owns 329,291 shares of the company’s stock worth $847,000 after purchasing an additional 50,194 shares during the last quarter. HighTower Advisors LLC bought a new position in Leap Therapeutics in the 3rd quarter worth approximately $65,000. HB Wealth Management LLC raised its stake in Leap Therapeutics by 103.2% during the 4th quarter. HB Wealth Management LLC now owns 51,500 shares of the company’s stock valued at $150,000 after acquiring an additional 26,150 shares in the last quarter. Monaco Asset Management SAM acquired a new position in Leap Therapeutics during the 4th quarter worth $592,000. Finally, Key Client Fiduciary Advisors LLC grew its stake in shares of Leap Therapeutics by 12.2% in the fourth quarter. Key Client Fiduciary Advisors LLC now owns 361,253 shares of the company’s stock worth $1,039,000 after purchasing an additional 39,330 shares in the last quarter. Institutional investors and hedge funds own 30.46% of the company’s stock.

Analyst Upgrades and Downgrades

LPTX has been the subject of several research analyst reports. Baird R W downgraded shares of Leap Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Wednesday, January 29th. Robert W. Baird cut Leap Therapeutics from an “outperform” rating to a “neutral” rating and dropped their target price for the stock from $9.00 to $1.25 in a report on Wednesday, January 29th. Finally, HC Wainwright lowered Leap Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, January 29th.

Leap Therapeutics Trading Down 2.2 %

NASDAQ:LPTX opened at $0.40 on Friday. The company has a 50-day moving average of $0.94 and a 200-day moving average of $2.25. The firm has a market cap of $15.37 million, a price-to-earnings ratio of -0.21 and a beta of 0.35. Leap Therapeutics, Inc. has a twelve month low of $0.39 and a twelve month high of $4.79.

About Leap Therapeutics

Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops antibody therapies for the treatment of cancer. Its lead product candidates include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in multiple ongoing clinical trials for treating esophagogastric and gynecologic cancers; and FL-301, a monoclonal antibody that targets cells that express Claudin18.2 on their cell surface and is in phase II clinical trial, as well as two preclinical antibody programs, FL-302 and FL-501.